Difference between revisions of "Carmustine (BCNU)"
Jump to navigation
Jump to search
(updated content) |
|||
| Line 9: | Line 9: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | *[[Central nervous system (CNS) cancer]] | ||
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
*[[Melanoma]] | *[[Melanoma]] | ||
| − | |||
*[[Transplant conditioning regimens]] | *[[Transplant conditioning regimens]] | ||
Revision as of 02:20, 23 June 2013
Also known as bischloroethylnitrosourea, BCNU, or Carustine.
General information
Class/mechanism: Nitrosourea, alkylates DNA and RNA, inhibits several key enzymatic processes by carbamoylation of amino acids in proteins.[1][2]
Route: IV
Extravasation: vesicant/irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Carmustine (BiCNU) patient drug information (Chemocare)[3]
- Carmustine (BiCNU) patient drug information (UpToDate)[4]